Table 2.

Description of trials assessing the outcome of metabolic surgery on type 2 diabetes mellitus.

TrialCitationParticipantsFollow-upInterventionsPrimary end pointsOutcome
STAMPEDESchauer et al. (53)N = 1345 yearsRYGB (n = 49)
VSG (n = 47)
Intensive medical therapy (n = 38)
HbA1c ≤ 6.0% at 5 years with or without diabetes medication29% (n = 14)
23% (n = 11)
5% (n = 2)
DIBASYMingrone et al. (54)N = 602 yearsRYGB (n = 20)
BPD (n = 20)
Medical therapy (n = 20)
Diabetes remission (fasting glucose < 101 mg/dL and HbA1c ≤ 6.5% in the absence of diabetes medication75% (n = 15)
95% (n = 19)
0% (n = 0)
CROSSROADSCummings et al. (55)N = 321 yearRYGB (n = 15)
Medical therapy (n = 17)
HbA1c < 6.0% in absence of diabetes medication60% (n = 9)
5.9% (n = 1)
Diabetes surgery studyIkramuddin et al. (56)N = 1801 yearRYGB (n = 60)
Intensive medical therapy (n = 120)
HbA1c < 7.0%49% (n = 28)
19% (n = 11)
Prospective, randomized trials of gastric bypass surgery in patients with type 2 diabetes mellitusLee et al. (57)N = 601 yearRYGB (n = 30)
VSG (n = 30)
Diabetes remission (fasting glucose < 126 mg/dl and HbA1c ≤ 6.5% without glycemic therapy93% (n = 28)
47% (n = 14)
Lee et al. (58)N = 322 yearsRYGB (n = 16)
VSG (n = 16)
Complete diabetes remission (fasting glucose < 110 mg/dL and HbA1c ≤ 6.0% and without glycemic therapy56% (n = 9)
6% (n = 1)
RYGB (n = 16)
VSG (n = 16)
Partial diabetes remission (fasting glucose <126 mg/dl and HbA1c ≤ 6.5%)81% (n = 13)
19% (n = 3)
  • RYGB, Roux-en-Y gastric bypass; VSG, vertical sleeve gastrectomy; BPD, biliopancreatic diversion with duodenal switch; HbA1c, hemoglobin A1c.

  • To convert mg/dL to mmol/L, multiply glucose by 0.05551.